SCHEMBL20023052

SCHEMBL20023052

CCc1ccc(C(=O)CCCC(=O)C(=O)OCc2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.46
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 3/20 0.45
KMT2A Q03164 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
RAB9A P51151 4/20 0.44
NPC1 O15118 4/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
MAPT P10636 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 1/20 0.44
PDE4B Q07343 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
EGFR P00533 2/20 0.43
GAA P10253 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20023040 0.89 TDP1 (0.56) DPP4LMNATDP1KMT2ASLC6A2
SCHEMBL20023032 0.86 TDP1 (0.58) DPP4LMNATDP1KMT2ASLC6A2
SCHEMBL20023091 0.86 PDE4B (0.63) KMT2ARAB9ANPC1MAPTPDE4B
SCHEMBL20023029 0.85 L3MBTL1 (0.51) DPP4LMNATDP1KMT2ASLC6A2
SCHEMBL20023036 0.85 TDP1 (0.61) DPP4LMNATDP1KMT2ASLC6A2
SCHEMBL20023063 0.85 USP5 (0.50) DPP4LMNATDP1KMT2ASLC6A2
SCHEMBL20023060 0.84 ERCC5 (0.50) DPP4TDP1RAB9ANPC1CASP3
SCHEMBL20023093 0.84 NPC1 (0.59) DPP4RAB9ANPC1MAPTALDH1A1
SCHEMBL20023061 0.83 NPC1 (0.62) DPP4KMT2ARAB9ANPC1MAPT
SCHEMBL20023049 0.83 HDAC1 (0.55) DPP4LMNATDP1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors ASAH2, GBA1, GAA DPP4 1330/4885LMNA 1311/4885TDP1 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.